Compass Therapeutics Proposes 1-for-25 Reverse Stock Split for Nasdaq Listing
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
reverse-stock-splitbiotech
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Compass Therapeutics, Inc. detailed a proposal for a 1-for-25 reverse stock split in its definitive proxy statement filed on 4 June 2026 for a shareholder meeting scheduled for 3 July. The biopharmaceutical company, trading under the ticker CMPX, seeks to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The stock last traded around $0.16, placing it at risk of delistment.
Reverse stock splits have been a recurring survival mechanism for small-cap biotech firms facing prolonged bear markets. In the fourth quarter of 2025, over 15 Nasdaq-listed biotech companies executed splits to maintain their listings. The current macro backdrop features elevated short-term interest rates, which have dried up speculative capital for early-stage drug developers.
What triggered the event now is a formal notice from Nasdaq. The exchange mandates a minimum bid price of $1.00 for continued listing. Compass Therapeutics received a deficiency notice after its stock traded below that threshold for 30 consecutive business days. The company's 180-day compliance period is nearing its end, forcing action.
The catalyst chain is straightforward. Without the reverse split, the stock faces delisting to the over-the-counter (OTC) market. An OTC listing severely reduces liquidity, institutional ownership, and access to capital. The board determined a reverse split was the only viable path to preserve a Nasdaq listing and future financing options.
The proposed 1-for-25 ratio is exceptionally aggressive. For every 25 pre-split shares, a shareholder will own one post-split share. The company's outstanding shares will collapse from approximately 187.5 million to about 7.5 million. The authorized shares will reduce proportionally from 300 million to 12 million.
A comparison shows the scale of adjustment needed. The table below illustrates the intended effect.
| Metric | Pre-Split | Post-Split (Target) |
|---|---|---|
| Share Price | ~$0.16 | ~$4.00 |
| Outstanding Shares | ~187.5M | ~7.5M |
| Market Capitalization | ~$30M | ~$30M |
The post-split price target of $4.00 is based on the pre-split price. This target is four times Nasdaq's $1.00 minimum. In contrast, the iShares Biotechnology ETF (IBB) has a constituent weighted average price above $50. The S&P 500 Health Care sector index trades above $100 per share.
The second-order effect is a potential recalibration of risk in the micro-cap biotech sector. Companies like Atreca (BCEL) and Kronos Bio (KRON), which have also traded below $1, may face increased scrutiny to undertake similar measures. Brokerage firms often impose restrictions on clients buying sub-$1 stocks, further pressuring these tickers.
One acknowledged limitation is that a reverse split does not alter a company's fundamental value. It is a purely cosmetic accounting change. The market capitalization remains unchanged, and the underlying business challenges persist. Historical data shows many reverse-split stocks continue to decline post-split without a material improvement in operations.
Positioning shows institutional ownership in CMPX is minimal. Retail investors hold a significant portion of the float. Flow is likely moving towards passive index funds in larger, profitable healthcare names like Eli Lilly (LLY) and Novo Nordisk (NVO). Short interest in CMPX is elevated, reflecting skepticism about the company's turnaround prospects.
The primary catalyst is the shareholder vote on 3 July 2026. Approval requires a majority of the outstanding shares. If approved, the company will announce the effective split date shortly after. Investors should also monitor any concurrent financing announcement, which sometimes accompanies such proposals.
Levels to watch include the post-split price's stability above the $1.00 Nasdaq minimum. A failure to hold above $1.00 could trigger another deficiency notice. Key resistance for CMPX post-split may be found at its 50-day moving average, which would need to be recalculated after the split occurs.
Conditional outcomes are clear. If the vote fails, expect immediate delisting proceedings to the OTCQB market. If the vote passes but the stock price drifts back below $1.00 within months, it signals a lack of fundamental investor interest, potentially leading to another reverse split cycle.
A reverse split is typically a neutral event for fundamental valuation but carries a negative market signal. It does not change the company's total market value. However, it is often a last-resort action to avoid delisting, indicating the stock has performed poorly. Post-split, the stock can be more volatile due to reduced liquidity from fewer outstanding shares.
Shareholders who end up with fractional shares after the 1-for-25 consolidation will not receive fractional share certificates. Instead, the company's transfer agent will aggregate all fractional shares, sell them on the open market, and distribute the net cash proceeds to the affected shareholders. This is a standard practice known as cash-in-lieu of fractional shares.
The 1-for-25 ratio is at the extreme end of the scale for 2026. More common ratios have been 1-for-10 or 1-for-15. The aggressive ratio reflects how far Compass Therapeutics' stock price had fallen below the Nasdaq minimum. It also results in a very low share count, which can increase bid-ask spreads and make the stock less attractive to some institutional investors.
Compass Therapeutics' drastic reverse split is a defensive move to retain its Nasdaq listing, not an indicator of improved business fundamentals.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.